Viemed sees boost from Lehan’s in Q3

LAFAYETTE, La. – Viemed Healthcare reported revenue of $71.9 million for the third quarter 2025, a 24% increase compared to the previous quarter in 2024. Adjusted EBITDA totaled $16.1 million, a 15.5% increase. 

During the quarter: 

• Viemed repurchased and cancelled 1,706,380 common shares under its share repurchase program at a cost of $11.4 million, representing an average buyback price of $6.68 per share; and 
• Closed on its acquisition of Lehan’s Medical Equipment. 

"We delivered another outstanding quarter marked by strong execution and sustained expansion of our patient base across every major service line,” said Casey Hoyt, CEO. “Our disciplined approach to capital deployment was demonstrated through the full completion of our 2025 share repurchase program, while the acquisition of Lehan's Medical Equipment further enhanced our market presence and diversified our service capabilities. Both initiatives were accretive to earnings per share and reflect our unwavering commitment to creating long-term shareholder value while improving patient outcomes across the communities we serve." 

Viemed increased its ventilator patient count to 12,372 as of the end of September, an increase of 8.8% over September 2024. It increased its PAP therapy patient count to 31,891, an increase of 63.7%. 

The company is updating its financial guidance for the year ending Dec. 31, 2025, as follows: 

• Net revenue: Now expected to be in the range of $271 million to $273 million, compared to the previous guidance of $271 million to $277 million. 
• Adjusted EBITDA: Now expected to be in the range of $60 million to $62 million, compared to the previous guidance of $59 million to $62 million.